^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Minerval (idroxioleic acid)

    i
    Other names: LP561A1, 2-hydroxy-9-cis octadecenoic, 2-OHOA, LAM561, LAM 561, LAM-561
    Associations

    News

    Trials
    Company:
    Laminar Pharma
    Drug class:
    Sphingomyelin synthase activator
    Associations

    News

    Trials
    3ms
    Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=28, Recruiting, Laminar Pharmaceuticals | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Jun 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Minerval (idroxioleic acid)
    3ms
    CLINGLIO: LAM561 With RT and TMZ for Adults With Glioblastoma (clinicaltrials.gov)
    P2/3, N=144, Active, not recruiting, Laminar Pharmaceuticals | Trial completion date: May 2025 --> Nov 2026 | Trial primary completion date: Oct 2024 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation • IDH wild-type
    |
    temozolomide • Minerval (idroxioleic acid)
    over1year
    Targeting the Notch-Furin axis with 2-hydroxyoleic acid: a key mechanism in glioblastoma therapy. (PubMed, Cell Oncol (Dordr))
    These findings report that the inhibition of Notch signaling by 2OHOA plays a role in its anti-tumoral activity, an effect that may be driven through direct inhibition of furin, characterizing a novel target of this bioactive lipid to treat GBM.
    Journal
    |
    NOTCH2 (Notch 2) • NOTCH3 (Notch Receptor 3) • HES1 (Hes Family BHLH Transcription Factor 1)
    |
    HES1 overexpression
    |
    Minerval (idroxioleic acid)
    over1year
    CLINGLIO: LAM561 With RT and TMZ for Adults With Glioblastoma (clinicaltrials.gov)
    P2/3, N=140, Active, not recruiting, Laminar Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    temozolomide • Minerval (idroxioleic acid)
    almost2years
    Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=28, Recruiting, Laminar Pharmaceuticals | N=18 --> 28 | Trial completion date: Nov 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Jun 2025
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    Minerval (idroxioleic acid)
    almost2years
    CLINGLIO: LAM561 With RT and TMZ for Adults With Glioblastoma (clinicaltrials.gov)
    P2/3, N=140, Recruiting, Laminar Pharmaceuticals | Trial primary completion date: Feb 2024 --> Oct 2024
    Trial primary completion date • Combination therapy
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation • IDH wild-type
    |
    temozolomide • Minerval (idroxioleic acid)
    almost2years
    Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Laminar Pharmaceuticals | Trial completion date: Jun 2024 --> Nov 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Minerval (idroxioleic acid)
    over2years
    A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma. (PubMed, Br J Cancer)
    2-OHOA demonstrated a good safety profile and encouraging activity in this difficult-to-treat malignant brain-tumour patient population, placing it as an ideal potential candidate for the treatment of glioma and other solid tumour malignancies.
    P1/2 data • Journal
    |
    Minerval (idroxioleic acid)
    over3years
    CLINGLIO: 2-OHOA With RT and TMZ for Adults With Glioblastoma (clinicaltrials.gov)
    P2/3, N=140, Recruiting, Laminar Pharmaceuticals | Trial completion date: Oct 2023 --> May 2025 | Trial primary completion date: Apr 2022 --> Feb 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation • IDH wild-type
    |
    temozolomide • Minerval (idroxioleic acid)
    over3years
    Anti-Tumorigenic Effect of a Novel Derivative of 2-Hydroxyoleic Acid and the Endocannabinoid Anandamide on Neuroblastoma Cells. (PubMed, Biomedicines)
    Finally, we observed that combined treatment of HU-585 with the senolytic drugs ABT-263 in vitro, and ABT-737 in vivo resulted in enhanced anti-proliferative effects and reduced neuroblastoma xenograft growth in comparison to treatment with HU-585 alone. Based on these results, we suggest that HU-585 is a pro-apoptotic and senescence-inducing compound, better than HU-600. Hence, it may be a beneficial option for the treatment of resistant neuroblastoma especially when combined with senolytic drugs that enhance its anti-tumorigenic effects.
    Journal
    |
    CASP3 (Caspase 3)
    |
    navitoclax (ABT 263) • ABT-737 • Minerval (idroxioleic acid)
    over4years
    CLINGLIO: 2-OHOA With RT and TMZ for Adults With Glioblastoma (clinicaltrials.gov)
    P2/3, N=180, Recruiting, Laminar Pharmaceuticals | Active, not recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation
    |
    temozolomide • Minerval (idroxioleic acid)